Enginprime Medical Secures $12 Million Series A Financing
Enginprime Medical has closed a $12 million Series A financing round, exclusively led by Qiming Venture Partners. The funds will support the company's China registration trial and overseas early-stage clinical development.
Enginprime Medical, a developer of percutaneous ventricular devices, announced on August 17, 2026, that it has secured $12 million in Series A financing. The round was exclusively led by Qiming Venture Partners.
The capital raised is earmarked to fund the company's upcoming registration trial in China and to support its early-stage clinical development efforts internationally. This funding is expected to accelerate the company's product development pipeline.
Enginprime Medical focuses on creating advanced medical technologies aimed at improving patient outcomes. The successful financing positions the company to advance its key projects through critical regulatory and clinical milestones.
Further details regarding the company's specific product roadmap and the timeline for initiating trials are anticipated in the coming months.